SG&A Efficiency Analysis: Comparing Viatris Inc. and Viridian Therapeutics, Inc.

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Viatris Inc. and Viridian Therapeutics, Inc. present a fascinating case study. Over the past decade, Viatris has consistently demonstrated a robust SG&A strategy, with expenses peaking at approximately $4.65 billion in 2023, marking a 210% increase since 2014. In contrast, Viridian Therapeutics, while smaller in scale, has shown a remarkable 1,125% growth in SG&A expenses, reaching nearly $95 million in 2023. This stark contrast highlights the differing scales and strategies of these companies. Viatris's steady growth reflects its established market presence, while Viridian's rapid increase suggests aggressive expansion efforts. As the industry continues to evolve, these trends offer valuable insights into the strategic priorities of pharmaceutical giants and emerging players alike.

Key Insights

• Viatris's SG&A expenses grew by 210% from 2014 to 2023.
• Viridian's SG&A expenses surged by 1,125% in the same period.